Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Eli Lilly and Company et al v. Genentech, Inc. et al
Case Number:
2:13-cv-07248
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 06, 2015
Genentech Blood Cancer IP Not Double-Patented, Judge Rules
A California federal judge declined to invalidate two Genentech Inc. patents covering biotechnology used to make drugs for cancer and autoimmune diseases, ruling Thursday that Eli Lilly and Co.'s arguments that the method was double-patented were unpersuasive.
-
October 30, 2013
Genentech Seeks Trim Of Eli Lilly's Patent Invalidation Suit
Genentech Inc. on Wednesday urged a California federal judge to trim a suit seeking to invalidate its patents for a blood cancer treatment, saying Eli Lilly and Co. had failed to show a Genentech attorney and others engaged in inequitable conduct in prosecuting the patents.